Inventor · disambiguated record
Zhili Xin
Also filed as: XIN ZHILI
42 granted patents·24 pending applications·625 citations·filing 1995–2024
97Inventor score
Top patents by PatentIndex Score
66 records- 0194US6160109APreparation of phosphorothioate and boranophosphate oligomersISIS PHARMACEUTICALS INC·Filed 1998·Granted Dec 12, 2000·255 cites·54 claims
- 0292US7119205B2Thienopyridones as AMPK activators for the treatment of diabetes and obesityABBOTT LAB·Filed 2004·Granted Oct 10, 2006·47 cites·14 claims
- 0390US7169797B2Protein-tyrosine phosphatase inhibitors and uses thereofABBOTT LAB·Filed 2004·Granted Jan 30, 2007·33 cites·12 claims
- 0488US9771326B2S1P and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Sep 26, 2017·6 cites·11 claims
- 0588US6031092APreparation of phosphorothioate oligomersMC GILL UNIVERSITY·Filed 1997·Granted Feb 29, 2000·40 cites·27 claims
- 0687US5734041APreparation of chiral phosphorothioate oligomersUNIV MCGILL·Filed 1995·Granted Mar 31, 1998·75 cites·36 claims
- 0786US9550798B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 24, 2017·8 cites·25 claims
- 0885US9555050B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 31, 2017·4 cites·24 claims
- 0984US9850206B2S1P and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Dec 26, 2017·4 cites·22 claims
- 1084US7968536B2Heterocyclic compounds useful as RAF kinase inhibitorsMILLENNIUM PHARM INC·Filed 2008·Granted Jun 28, 2011·9 cites·31 claims
- 1184US7888374B2Inhibitors of c-jun N-terminal kinasesABBOTT LAB·Filed 2006·Granted Feb 15, 2011·9 cites·23 claims
- 1284US6861518B2Preparation of phosphorothioate oligomersUNIV MCGILL·Filed 2002·Granted Mar 1, 2005·17 cites·14 claims
- 1383US6878700B1Cell adhesion-inhibiting antiinflammatory and immune-suppressive compoundsABBOTT LAB·Filed 2000·Granted Apr 12, 2005·14 cites·7 claims
- 1482US9522889B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Dec 20, 2016·5 cites·31 claims
- 1582US5945521APreparation of phosphorothioate oligomersUNIV MCGILL·Filed 1997·Granted Aug 31, 1999·50 cites·23 claims
- 1681US8802657B2Compounds useful as Raf kinase inhibitorsMILLENNIUM PHARM INC·Filed 2012·Granted Aug 12, 2014·4 cites·19 claims
- 1780US12275728B2O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2024·Granted Apr 15, 2025·0 cites·2 claims
- 1880US11814362B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2019·Granted Nov 14, 2023·1 cites·16 claims
- 1980US8293752B2Compounds useful as Raf kinase inhibitorsCHEN WEIRONG·Filed 2008·Granted Oct 23, 2012·6 cites·13 claims
- 2079US9499485B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Nov 22, 2016·4 cites·14 claims
- 2178US7115767B2Tetraline derivatives as ghrelin receptor modulatorsABBOTT LAB·Filed 2004·Granted Oct 3, 2006·9 cites·21 claims
- 2273US12404263B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 2366US6972340B2Selective protein tyrosine phosphatatase inhibitorsABBOTT LAB·Filed 2001·Granted Dec 6, 2005·3 cites·72 claims
- 2460US6110922ACell adhesion-inhibiting antiinflammatory and immune-suppressive compoundsABBOTT LAB·Filed 1998·Granted Aug 29, 2000·16 cites·19 claims
- 2560US2025152574A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2660US2025171463A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2760US2025161281A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2860US2025304577A1Tyk2 inhibitorsBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2959US2005171132A1Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonistsFiled 2004·Application pending·0 cites
- 3058US8076344B2Inhibitors of diacylglycerol O-acyltransferase type 1 enzymeLIU GANG·Filed 2008·Granted Dec 13, 2011·0 cites·13 claims
- 3158US2021340107A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 3257US12180205B2O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Dec 31, 2024·0 cites·20 claims
- 3357US2023117898A1O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitorsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 3455US9920048B2Substituted pyrimidines for inhibiting Raf kinase activityMILLENNIUM PHARM INC·Filed 2016·Granted Mar 20, 2018·0 cites·13 claims
- 3554US2006287356A1Thienopyridones as AMPK activators for the treatment of diabetes and obesityIYENGAR RAJESH R·Filed 2006·Application pending·0 cites
- 3653US2025268877A12h-indazole derivatives as irak4 inhibitors and their use in the treatment of diseaseBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 3753US2024116922A1Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of diseaseBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 3852US10968181B2NRF2 activatorBIOGEN MA INC·Filed 2017·Granted Apr 6, 2021·0 cites·24 claims
- 3952US2016039825A1S1p and/or atx modulating agentsBIOGEN MA INC·Filed 2014·Application pending·0 cites
- 4051US8202878B2Inhibitors of diacylglycerol O-acyltransferase type 1 enzymeSOUERS ANDREW J·Filed 2007·Granted Jun 19, 2012·0 cites·8 claims
- 4150US12421224B2Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2020·Granted Sep 23, 2025·0 cites·20 claims
- 4250US2012040951A1Heteroaryl compounds useful as raf kinase inhibitorsCHUAQUI CLAUDIO·Filed 2009·Application pending·0 cites
- 4349US8557828B2Inhibitors of diacylglycerol O-acyltransferase type 1 enzymeLIU GANG·Filed 2011·Granted Oct 15, 2013·0 cites·14 claims
- 4449USRE39197ECell adhesion-inhibiting antiinflammatory and immune-suppressive compoundsABBOTT LAB·Filed 2002·Granted Jul 18, 2006·0 cites·35 claims
- 4549US2005171131A1Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonistsFiled 2004·Application pending·0 cites
- 4648US11459324B2O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Oct 4, 2022·0 cites·21 claims
- 4748US9944666B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2016·Granted Apr 17, 2018·0 cites·15 claims
- 4848US2004097722A9Preparation of phosphorothioate oligomersUNIV MCGILL·Filed 2003·Application pending·0 cites
- 4947US10017506B2ATX modulating agentsBIOGEN MA INC·Filed 2016·Granted Jul 10, 2018·0 cites·21 claims
- 5046US12319679B2Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Jun 3, 2025·0 cites·18 claims
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zhili Xin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →